Developing the Next Generation of Ex Vivo Delivery Technologies

<div class="ag87-crtemvc-hsbk"><div class="css-vsf5of"><p class="carina-rte-public-DraftStyleDefault-block"><span style="color: rgb(29,28,29);">The uptake of macromolecules by fragile cell types remains an important problem in both R&amp;D and manufacturing of personalized medicines. Existing viral and non-viral delivery options have significant limitations for cell engineering and cell therapy development. Can next-generation delivery technology improve efficiency and viability when modifying fragile cells? What if silicon semiconductor technology could be utilized to deliver single-cell precision at scale? New ex vivo delivery approaches are simplifying the development of therapeutic pipelines and accelerating the creation of new cell and gene therapies.</span></p></div></div>